Fingerprint
Dive into the research topics of 'Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically